The Enterprise Value as of November 2024 (TTM) for Pliant Therapeutics, Inc. (PLRX) is 770.48M

According to Pliant Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 770.48M. This represents a change of -2.52% compared to the average of 790.41M of the last 4 quarters.

Pliant Therapeutics, Inc. (PLRX) Historical Enterprise Value (quarterly & annually)

How has PLRX Enterprise Value performed in the past?

The mean historical Enterprise Value of Pliant Therapeutics, Inc. over the last ten years is 568.35M. The current 770.48M Enterprise Value has changed 13.46% with respect to the historical average. Over the past ten years (40 quarters), PLRX's Enterprise Value was at its highest in in the March 2023 quarter at 1.40B. The Enterprise Value was at its lowest in in the June 2019 quarter at 0.

Pliant Therapeutics, Inc. (PLRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Pliant Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Pliant Therapeutics, Inc. (PLRX) Average Enterprise Value

How has PLRX Enterprise Value performed in the past?

The current Enterprise Value of Pliant Therapeutics, Inc. (PLRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Pliant Therapeutics, Inc. (PLRX) Enterprise Value vs. Peers

How is PLRX’s Enterprise Value compared to its peers?

Pliant Therapeutics, Inc.’s Enterprise Value is greater than Relay Therapeutics, Inc. (692.53M), greater than Stoke Therapeutics, Inc. (457.69M), greater than Black Diamond Therapeutics, Inc. (139.97M), less than Arvinas, Inc. (1.69B), less than 89bio, Inc. (940.63M), less than Madrigal Pharmaceuticals, Inc. (7.46B), less than Arcellx, Inc. (4.79B), less than Dyne Therapeutics, Inc. (2.51B), less than Cytokinetics, Incorporated (6.54B), less than Revolution Medicines, Inc. (9.43B), less than Syndax Pharmaceuticals, Inc. (1.24B), less than Viridian Therapeutics, Inc. (1.42B), greater than Inozyme Pharma, Inc. (202.73M), greater than TCR2 Therapeutics Inc. (79.12M), greater than Atreca, Inc. (-8620212.00), greater than Passage Bio, Inc. (24.72M),

Build a custom stock screener for Pliant Therapeutics, Inc. (PLRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pliant Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Pliant Therapeutics, Inc. (PLRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Pliant Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.